Figure 5. Kaplan-Meier Estimates of the Time to Virologic Failure after Achieving Viral Suppression Antiretroviral Therapy Related to Base-Line Phenotypic Resistance Data Obtained During Acute or Early HIV Infection

Figure 5. Kaplan-Meier Estimates of the Time to Virologic Failure after
Achieving Viral Suppression Antiretroviral Therapy Related to Base-Line Phenotypic
Resistance Data Obtained During Acute or Early HIV Infection

Kaplan-Meier Estimates of the Time to Virologic Failure Related to Base-Line Drug Susceptibility. The IC50 result was obtained from phenotypic resistance test and represents the concentration of the antiretroviral drug required to cause 50% inhibition of HIV replication; these results are compared with the IC50 of a drug-sensitive reference strain to determine the IC50 ratio. The graph line with IC50 ratio less than 2.5 represents patients with drug-susceptible HIV, whereas the graph line with IC50 ratio greater than 10 represents those patients who had resistance to at least one antiretroviral drug. Among the patients who achieved an HIV RNA less than 500 copies/ml, the subsequent time to virologic failure was significantly shorter in those with base-line resistant HIV. Results from the resistance testing were not known when the patients received antiretroviral therapy. The tick marks indicate censored subject data because of inadequate monitoring of HIV RNA levels as well as for patients who interrupted therapy for longer than 14 days. Figure reproduced from Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-94. Reproduced with permission from the Massachusetts Medical Society. Copyright © 2002 Massachusetts Medical Society. All rights reserved.

[Close Window]